Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
24 Mar 22
Current reports
8-K
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
16 Apr 24
8-K
Regulation FD Disclosure
10 Apr 24
8-K
Monopar Reports Fourth Quarter and Full-Year 2023
28 Mar 24
8-K
Regulation FD Disclosure
7 Mar 24
8-K
Monopar Announces Positive Preclinical Therapeutic Isotope Data
5 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Feb 24
8-K
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
27 Feb 24
8-K
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
22 Feb 24
8-K
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical
20 Feb 24
8-K
Monopar Therapeutics Reports Third Quarter 2023
9 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
4 Jan 23
S-3
Shelf registration
21 Dec 22
S-8
Registration of securities for employees
12 Aug 22
424B5
Prospectus supplement for primary offering
20 Apr 22
S-8
Registration of securities for employees
13 Nov 20
424B5
Prospectus supplement for primary offering
13 Jan 20
S-3
Shelf registration
3 Jan 20
S-8
Registration of securities for employees
3 Jan 20
424B4
Prospectus supplement with pricing info
19 Dec 19
S-1/A
IPO registration (amended)
13 Dec 19
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
3 May 21
DEF 14A
Definitive proxy
30 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
DEF 14C
Information statement
21 May 19
DEF 14C
Information statement
20 Apr 18
Other
EFFECT
Notice of effectiveness
5 Jan 23
CORRESP
Correspondence with SEC
29 Dec 22
UPLOAD
Letter from SEC
28 Dec 22
EFFECT
Notice of effectiveness
14 Jan 20
CORRESP
Correspondence with SEC
10 Jan 20
UPLOAD
Letter from SEC
10 Jan 20
EFFECT
Notice of effectiveness
19 Dec 19
CORRESP
Correspondence with SEC
17 Dec 19
CORRESP
Correspondence with SEC
16 Dec 19
CORRESP
Correspondence with SEC
7 Nov 19